Evercore ISI analyst Vijay Kumar raised the firm’s price target on Danaher to $278 from $275 and keeps an Outperform rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q3 preview.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher initiated with an Overweight at Stephens
- Danaher put volume heavy and directionally bearish
- Danaher backs FY24 revenue growth down in low-single digits from $23.89B in FY23
- Danaher still sees Q3 non-GAAP revenue down in low-single digits year-over-year
- Wells Fargo sees more downside than upside, starts Danaher with Equal Weight